Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

• Status: Terminated
• Trial end date: 2020-09-25
• Target enrollment: 0
• Participant gender: All

Summary

All patients with pulmonary blastomycosis requiring mechanical ventilation will have their blood concentrations measured for the antifungal drugs, amphotericin-B and voriconazole; as well as an analysis of the susceptibility of their infecting species of blastomyces. This information will then be analyzed relative to their rate of clinical recovery from this serious fungal infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Manitoba
• Collaborator: Pfizer
• Treatments: Amphotericin B; Liposomal amphotericin B; Voriconazole

Criteria

Inclusion Criteria:

• All adult patients 18 years of age or older admitted to the intensive care units of St. Boniface General Hospital with a diagnosis of acute pulmonary blastomycosis requiring mechanical ventilation.

Exclusion Criteria:

• The patient's data will be excluded if they die within 3 days of hospital admission.